CCND1 and cancer: The biological significance of the AR-induced inhibition of cyclin D1 expression is highlighted by clinical studies in ERα-positive breast cancers, showing a better response to adjuvant therapy in cancer patients with cyclin D1 low/moderate expression than those with high expression of cyclin D1 [73, 74].